We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Complete Neanderthal Mitochondrial Genome Sequenced from Bone

By LabMedica International staff writers
Posted on 12 Sep 2008
Recent research has revealed the complete mitochondrial genome of a 38,000-year-old Neanderthal (Homo neanderthalensis). More...
The findings provide insights into the Neanderthals' past and help answer remaining questions about their relationship to modern humans.

"For the first time, we've built a sequence from ancient DNA that is essentially without error,” said Dr. Richard Green from the Max Planck Institute for Evolutionary Anthropology (Leipzig Germany), who published his findings in the August 8, 2008, issue of the journal Cell .

The investigators sequenced Neanderthal mitochondria DNA--including 13 protein-coding genes--nearly 35 times over. That remarkable coverage allowed them to sift out those differences between the Neanderthal and human genomes resulting from damage to the degraded DNA extracted from ancient bone versus real evolutionary changes.

Although it is well established that Neanderthals are the hominid form most closely related to modern-day humans, their precise relationship remains uncertain, according to the researchers. The notion that Neanderthals and humans may have "mixed” is still a matter of some controversy.

Analysis of the new sequence confirms that the mitochondria of Neanderthal's falls outside the variation found in humans today, providing no proof of admixture between the two lineages although it remains a possibility. The data also demonstrate that the last common ancestor of Neanderthals and humans lived approximately 660,000 years ago, for about 140,000 years.

Of the 13 proteins encoded in the mitochondrial DNA, the researchers discovered that one, known as subunit 2 of cytochrome c oxidase of the mitochondrial electron transport chain (COX2), had experienced an unexpected number of amino acid substitutions in humans since the separation from Neanderthals. While the finding is fascinating, according to Dr. Green, it is not yet clear what it means.

"We also wanted to know about the history of the Neanderthal's themselves,” said Dr. Jeffrey Good, also of the Max-Planck Institute. For instance, the new sequence information revealed that Neanderthal's have fewer evolutionary alterations overall, but a greater number that alter the amino acid building blocks of proteins. One simple interpretation of that finding is that the Neanderthal's had a smaller population size than humans do, which makes natural selection less successful in removing mutations.

That theory is consistent with arguments made by other scientists based upon the geologic record, said co-author Johannes Krause. "Most argue there were a few thousand Neanderthals that wandered over Europe 40,000 years ago.” That smaller population might have been the result of the smaller size of Europe compared to Africa. The Neanderthals also would have had to deal with repeated glaciations, he noted.

"It's still an open question for the future whether this small group of Neanderthals was a general feature, or was this caused by some bottleneck in their population size that happened late in the game,” Dr. Green said. Eventually, they hope to get DNA sequence information for Neanderthals that predated the Ice Age, to look for a signature that their populations had been larger in the past.

To be precise, the Neanderthal mitochondrial genome presented in the new study is a useful precursor for the sequencing of the complete Neanderthal nuclear genome, according to the researchers, an accomplishment that their team already has well underway.

Related Links:

Max Planck Institute for Evolutionary Anthropology


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.